Weiyuan Synthetic Biotechnology Funding, Investors & Competitors

Weiyuan Synthetic Biotechnology has raised $319M across 5 funding rounds, most recently a $220M undisclosed-stage round in May 2026.

Last Weiyuan Synthetic Biotechnology funding round

$220M

Undisclosed stage · May 2026

Cumulative funding Weiyuan Synthetic Biotechnology raised

$319M

across 5 funding rounds

Key investors in Weiyuan Synthetic Biotechnology

  • Shunxi Fund
  • Beijing Medical and Health Industry Investment Fund
  • Henan CICC Huirong Fund Management
  • Tan Ruiqing
  • Matrix Partners China
  • Shenzhen Capital Group
  • SDIC Venture Capital
  • CCB Investments

Weiyuan Synthetic Biotechnology Overview

About Weiyuan Synthetic Biotechnology

Weiyuan Synthetic Biotechnology, founded in December 2021, develops synthetic biology solutions for the low-carbon, low-cost production of active pharmaceutical ingredients, high value-added natural products, and platform compounds. The company uses multi-carbon-source fermentation technology to replace glucose with cheaper carbon sources, addressing cost and food-security challenges in industrial biomanufacturing. It also provides contract development and manufacturing (CDMO) services, producing APIs, small molecules, and peptides for biopharma clients.


Founded

2021

HQ

ChinaChina

Status

Privately held

Customer focus

B2B

Revenue model

Product sales

Weiyuan Synthetic Biotechnology Funding History

Weiyuan Synthetic Biotechnology has raised a total of $319M across 5 funding rounds.

Weiyuan Synthetic Biotechnology's first fundraising round was a $14M seed round in July 2023. The most recent completed round was a $220M undisclosed-stage round in May 2026.

Weiyuan Synthetic Biotechnology funding rounds

Weiyuan Synthetic Biotechnology funding rounds
DateStageInvestorsRaisedDeal Summary
May 2026Undisclosed stageTan Ruiqing; Zhang Qibin; Xingyin Investment$220MWeiYuan Synthetic Biology (Weiyuan Synthetic Biotechnology) raised RMB 1.5 billion in a Series B financing round led by Zhang Qibin and Tan Ruiqing. The transaction was structured as an equity financing round for the synthetic biomanufacturing company, with the reported raise amount equivalent to about USD 214 million. The round provides growth capital for the company’s development and scale-up in synthetic bio-manufacturing. WeiYuan Synthetic Biology operates in synthetic biology and synthetic biomanufacturing, positioning itself in a sector focused on industrial-scale biological production. The company’s May 2026 financing adds to the capital entering China’s biotech and healthcare startup market, and the round is framed as a significant Series B for the business.
Mar 2026Series AHenan Investment Group Huirong Fund Management; Tan Ruiqing--
Jan 2026Undisclosed stageZhongguancun Youth Technology Venture Capital; Beijing New Materials Industry Investment Fund; CCB Investments; Beijing Medical and Health Industry Investment Fund$43M-
Aug 2024Series ASDIC Venture Capital (lead); Hebei Industrial Investment; Jing Guorui; Shenzhen Capital Group; Shenzhen Venture Capital; Shunxi Fund; Henan CICC Huirong Fund Management; Beijing Medical and Health Industry Investment Fund$42MWeiyuan Synthetic Biotechnology (微元合成生物技术), founded in December 2021, develops synthetic biology solutions for low-carbon, energy-saving production of compounds, including APIs, high value-added natural products, and platform compounds. The company leverages multi-carbon source utilization technology, replacing glucose with cheaper carbon sources to address cost and food security issues in biomanufacturing. It has designed pipelines for low-cost biomanufacturing of bulk materials to support scale-up and commercialization. Competitors include Bota Biotech, Bluepha, Synceres, and Abiochem. In May 2022, Weiyuan completed an angel round of nearly CNY 100 million led by Matrix Partner China, with participation from BioTrack Capital, Henan Investment Group Huirong Fund, K2VC, and Hoshi Capital. Funds were allocated to R&D labs, technology enhancement, and product pipeline development.
Jul 2023SeedShunxi Fund (lead); Matrix Partners China; Beidaihe New District High-tech Industry Fund; Henan CICC Huirong Fund Management$14MWeiyuan Synthetic Biotechnology, also referred to as Weiyuan Synthesis, is a CDMO focused on manufacturing API products for the biopharma sector, providing healthcare solutions, biopharma outsourcing, small molecules, peptides, and API production with client-centric approaches emphasizing high-quality outcomes, innovation, and sustainable practices. The company, headquartered in Beijing, China, operates in the healthcare sector. It raised a total of $13.85M across 2 strategic funding rounds, with the most recent being a Seed round of $13.85M in July 2023 led by Guoguan Shunxi Fund and involving 7 other investors including Henan Investment Group.

Who has invested in Weiyuan Synthetic Biotechnology?

17 investors have backed Weiyuan Synthetic Biotechnology across its funding rounds, including Shunxi Fund, Beijing Medical and Health Industry Investment Fund, Henan CICC Huirong Fund Management, Tan Ruiqing, Matrix Partners China and Shenzhen Capital Group.

Lead investors include SDIC Venture Capital and Shunxi Fund.


Weiyuan Synthetic Biotechnology Investors

Investors in Weiyuan Synthetic Biotechnology by funding rounds participated
InvestorHQRoundsRoleFirst check
Tan Ruiqing--2ParticipantMar 2026
Shunxi FundChinaBeijing2LeadJul 2023
Henan CICC Huirong Fund ManagementChinaZhengzhou2ParticipantJul 2023
Beijing Medical and Health Industry Investment FundChinaBeijing2ParticipantAug 2024
Matrix Partners ChinaChinaBeijing1ParticipantJul 2023
Zhongguancun Youth Technology Venture CapitalChinaBeijing1ParticipantJan 2026
Hebei Industrial InvestmentChinaShijiazhuang1ParticipantAug 2024
Henan Investment Group Huirong Fund ManagementChinaChina1ParticipantMar 2026
Jing GuoruiChinaChina1ParticipantAug 2024
Beijing New Materials Industry Investment FundChinaBeijing1ParticipantJan 2026
Zhang Qibin--1ParticipantMay 2026
Beidaihe New District High-tech Industry FundChinaQinhuangdao1ParticipantJul 2023
Shenzhen Capital GroupChinaShenzhen1ParticipantAug 2024

This data is available for Pro users. Sign up to see all 17 Weiyuan Synthetic Biotechnology investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Weiyuan Synthetic Biotechnology Competitors

Weiyuan Synthetic Biotechnology competitors include listed companies like CF Industries, Qinghai Salt Lake Industry, Industries Qatar and SABIC Agri-Nutrient, and private ones like Biobest and Agriprotein.

Public and private companies comparable to Weiyuan Synthetic Biotechnology
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
CF IndustriesUnited StatesUnited StatesPublicly listed$7.1B$3.2B$20B3.1x
Qinghai Salt Lake IndustryChinaChinaPublicly listed$2.3B$1.2B$20B4.5x
Industries QatarQatarQatarPublicly listed$4.4B$1.6B$17B4.4x
SABIC Agri-NutrientSaudi ArabiaSaudi ArabiaPublicly listed$3.5B$1.4B$16B4.1x
BiobestBelgiumWesterloPrivate--$1.5B-
AgriproteinSouth AfricaCape TownPrivate--$117M-

Weiyuan Synthetic Biotechnology Public Comps

Weiyuan Synthetic Biotechnology is still privately-owned, but its public comps include Corteva, BASF, Archer-Daniels-Midland, Nutrien, Muyuan Foods, Novonesis, Bunge, CF Industries, Qinghai Salt Lake Industry and Wilmar International.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Corteva$17B$2.9B3.3x3.2x19.5x13.9x
BASF$69B$8.2B1.1x1.0x8.9x8.6x
Archer-Daniels-Midland$80B$2.9B0.6x0.6x17.4x11.2x
Nutrien$27B$6.1B1.9x1.8x8.2x8.0x
Muyuan Foods$21B$5B2.0x2.3x8.7x16.1x
Novonesis$4.8B$1.6B7.1x6.7x21.7x17.9x
Bunge$70B$2.3B0.6x0.5x17.9x11.2x
CF Industries$7.1B$3.2B3.5x3.1x7.7x6.8x

This data is available for Pro users. Sign up to see all Weiyuan Synthetic Biotechnology competitors and their valuation data.

Start Free Trial

Common questions about Weiyuan Synthetic Biotechnology

When was Weiyuan Synthetic Biotechnology founded?Weiyuan Synthetic Biotechnology was founded in 2021.
Where is Weiyuan Synthetic Biotechnology headquartered?Weiyuan Synthetic Biotechnology is headquartered in China.
Is Weiyuan Synthetic Biotechnology publicly listed?No, Weiyuan Synthetic Biotechnology is a private, VC-backed company.
How much funding has Weiyuan Synthetic Biotechnology raised?Weiyuan Synthetic Biotechnology has raised $319M across 5 funding rounds.
What was Weiyuan Synthetic Biotechnology's last funding round?Weiyuan Synthetic Biotechnology's last funding round was a $220M undisclosed-stage round in May 2026.
Who are Weiyuan Synthetic Biotechnology's investors?Weiyuan Synthetic Biotechnology's investors include Tan Ruiqing, Shunxi Fund, Henan CICC Huirong Fund Management, Beijing Medical and Health Industry Investment Fund, Matrix Partners China, Zhongguancun Youth Technology Venture Capital, Hebei Industrial Investment, Henan Investment Group Huirong Fund Management, Jing Guorui, Beijing New Materials Industry Investment Fund and 7 others.
Which companies are comparable to Weiyuan Synthetic Biotechnology?Companies comparable to Weiyuan Synthetic Biotechnology include CF Industries, Qinghai Salt Lake Industry, Industries Qatar, SABIC Agri-Nutrient, Biobest and Agriprotein.

See companies similar to Weiyuan Synthetic Biotechnology

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial